Department of Thoracic Surgery, Yao Municipal Hospital, Osaka, Japan
Case Report
Marked Response after One Cycle of Pembrolizumab Monotherapy for Non-small Cell Lung Cancer: A Case Report and Brief Review of the Literature
Author(s): Ken Kodama*, Toru Momozane, Hiroshi Takehara, Junko Tanizaki and Kazuaki Sato*
Introduction: To date, there have been few reports of Non-Small Cell Lung Cancer (NSCLC) cases where a single cycle of pembrolizumab monotherapy led to near-complete tumor resolution without any adverse events.
Case Presentation: A 57-year-old woman with clinical stage IVB NSCLC and high Programmed Cell Death ligand 1 (PD-L1) expression of 95% received first-line pembrolizumab monotherapy. After only one cycle of the therapy, she experienced a significant improvement in respiratory symptoms and showed a nearly complete tumor response on CT. To date, the patient has received 15 cycles of pembrolizumab and sustained a complete response without any immune or treatment-related adverse events for 15 months.
Conclusion: Our literature search yielded 11 similar case reports in addition to this report. According to them, t.. View More»